The Gairdner Foundation is pleased to announce the 2025 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical and global health research and discoveries.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

Utility stocks are often considered a safe haven during economic troubles, and Dominion Energy (NYSE: D) stands out as a prime candidate. With a substantial customer base of 3.6 million in Virginia, ...

They were told they’d die young. Then a ‘miracle drug’ changed everything — and they have to grapple with what that means - ...

RBC Capital Markets adjusted its price target for Vertex to $420, maintaining a Sector Perform rating, based on promising early performance of Alyftrek, which is expected to cannibalize sales from ...

RBC Capital Markets adjusted its price target for Vertex to $420, maintaining a Sector Perform rating, based on promising early performance of Alyftrek, which is expected to cannibalize sales from ...

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...